Altre lingue Trevi Therapeutics, Inc.

Azioni

TRVI

US89532M1018

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
2,78 ^USD	+9,45%		-1,94%	+107,46%

20/03	Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
20/03	Trevi Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference	10/04
Trevi Therapeutics to Participate in Upcoming April Events	04/04
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team	02/04
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates	20/03
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024	13/03
Trevi Therapeutics to Participate in Upcoming March Events	28/02
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Trevi Therapeutics Provides Business Updates	04/01
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio for Chronic Cough in Idiopathic Pulmonary Fibrosis	06/12
Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)	05/12
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	05/12
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update	09/11
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio for Refractory Chronic Cough	03/11
Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough	02/11
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough	02/11
Trevi Therapeutics to Report Q3 2023 Financial Results and Provide a Corporate Update on November 9, 2023	01/11
Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio in Prurigo Nodularis	16/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Trevi Therapeutics, Inc.

Azioni

TRVI

US89532M1018

Altre lingue

Filtri